Literature DB >> 26056921

Synthesis, structural and theoretical studies of dithiodiglycolamide compounds of palladium(II).

Balgovind Vats1, S Kannan, Mahesh Sundararajan, Mukesh Kumar, M G B Drew.   

Abstract

The reaction of palladium(ii) halide with dithiodiglycolamide ligands yielded compounds of the type [PdX2L] (where X = Cl, L = (CH2SCH2CON(i)Pr2)2 (1); L = (CH2SCH2CON(i)Bu2)2 (2); L = (CH2SCH2CONBu2)2 (3); L = C7H6(SCH2CON(i)Bu2)2 (4); X = Br, L = (CH2SCH2CON(i)Bu2)2 (5); X = I, L = (CH2SCH2CON(i)Bu2)2 (6)), whereas palladium(ii) nitrate yielded compounds of the type [PdL2](NO3)2 (where L = (CH2SCH2CON(i)Pr2)2 (7); L = (CH2SCH2CON(i)Bu2)2 (8)). All compounds were characterized by using IR, (1)H NMR spectral techniques and CHN analyses. The structures of compounds 4, 5 and 7 have been determined by using X-ray diffraction methods. The structures show that the ligands bond through the thioether group to the metal centre in all compounds. They show further that the palladium(ii) ion is surrounded by four atoms (two halogens and two thio groups in 4 and 5 and four thio groups in 7) in a square planar arrangement. The dithiodiglycolamide ligand acts as a bidentate chelating ligand and bonds through both the thioether groups to the metal centre, leaving the carbamoyl groups uncoordinated. Theoretical studies reveal that the 1 : 2 compound is energetically more stable and nicely correlates with the IR carbamoyl stretching frequencies as compared to the 1 : 1 compound in which the ligand acts as a tetradentate ligand.

Entities:  

Year:  2015        PMID: 26056921     DOI: 10.1039/c4dt03814b

Source DB:  PubMed          Journal:  Dalton Trans        ISSN: 1477-9226            Impact factor:   4.390


  1 in total

1.  Molecular Docking and Preclinical Study of Five-Membered S,S-Palladaheterocycle as Hepatoprotective Agent.

Authors:  Nail Salavatovich Akhmadiev; Albina Midkhatovna Galimova; Vnira Rakhimovna Akhmetova; Veronika Radievna Khairullina; Rozaliia Akramovna Galimova; Eduard Feliksovich Agletdinov; Askhat Gabdrahmanovich Ibragimov; Valery Alekseevich Kataev
Journal:  Adv Pharm Bull       Date:  2019-10-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.